On March 10, 2022 Morningside Ventures reported the launch of Adiso Therapeutics, a clinical-stage biotechnology company advancing a pipeline of novel therapeutics targeting inflammatory diseases. Morningside has financed the Adiso development plans to date, with plans to further support the company’s rapid growth moving forward.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Adiso is advancing an innovative pipeline of small molecules with novel mechanisms of action and single strain live biotherapeutic products (SS-LBP), pursuing lead indications in ulcerative colitis (UC), and C. difficile infection (CDI). In addition to two Phase 1 programs (UC & CDI) and a Phase 2 program (UC), Adiso is developing a novel inflammasome program in the discovery phase which is being initially explored in respiratory inflammation, with multiple future potential therapeutic areas to pursue.
The company is comprised of 25 employees who previously, under the Morningside umbrella, successfully opened three Investigational New Drug (INDs) and have filed numerous patents as well as attaining U.S. FDA Fast Track Designation, ultimately leading to the formation of Adiso. Adiso will operate under the leadership of recently appointed Chief Executive Officer, Scott Megaffin. Mr. Megaffin possesses over 30 years of industry experience and a successful track record in senior leadership roles at Bristol-Myers Squibb, Pfizer, Schering-Plough, Adolor, Onconova, and Churchill. Most recently, Mr. Megaffin served as CEO of Adastra Pharmaceuticals, an oncology clinical-stage development company, where he guided the company to a successful transaction with Cothera Bioscience in October 2021.
"Critical unmet medical needs exist for new therapies that target the underlying biology of inflammatory diseases without causing systemic immunosuppression," said Jason Dinges, Morningside Technology Advisory and Adiso Board Member. "Adiso is sprinting out of the gate with three very promising clinical programs for the treatment of ulcerative colitis and the prevention of recurrent CDI. We believe that under Scott’s leadership and with a highly talented team of drug developers, Adiso is poised for success."
"At Adiso we are tackling inflammatory diseases with diverse mechanisms and a bold approach. We envision a new reality for patients, leveraging known advances of inflammatory therapeutics which promise to recalibrate the immune system of the host, so that the underlying inflammatory disease is neither overactivated nor does the patient become immunocompromised," said Scott Megaffin, CEO of Adiso Therapeutics. "I’m honored to be leading such an exceptional, world-class, and dedicated team at Adiso in the development of these highly unique therapies designed to precisely halt the dysregulation generated by inflammation."
(Press release, Adiso Therapeutics, MAR 10, 2022, View Source [SID1234670864])